Illumina Ventures

Founding Partner Nick Naclerio, Ph.D., leads the investment team and sets the firm's thesis. He is supported by partners including Abhijit Mazumder, Wouter Meuleman, and others, all of whom hold advanced scientific degrees. The firm operates with an independent investment committee despite its strategic link to Illumina.

No. Illumina Ventures is independently managed and makes its own investment decisions. While it maintains a strategic relationship with Illumina and benefits from access to its technology and expertise, it is not a captive corporate venture unit. The firm raises external capital and operates with a standard venture fund structure.

Illumina Ventures Labs is the firm's accelerator program for very early-stage genomics startups. Participating companies receive access to sequencing infrastructure, fully equipped lab space, mentorship from the firm's partners, and seed capital. The program acts as a pre-investment pipeline, often leading to a first institutional round led by Illumina Ventures.

The firm focuses tightly on genomics-enabled health and sustainability. It does not invest outside of its four stated verticals: life sciences tools, diagnostics, therapeutics, and digital health. Pure software plays, traditional healthcare services without a genomics component, and non-science-based consumer health apps fall outside the mandate.

Illumina Ventures leads Seed and Series A rounds in its core genomics verticals. The firm often acts as the first institutional investor, particularly for companies emerging from its Labs program. For later-stage financings within the portfolio, it participates as a follow-on investor, frequently alongside top-tier life sciences VCs.

Deal flow comes through three main channels: the Illumina Ventures Labs accelerator, which seeds pre-institutional companies; the strategic relationship with Illumina, which surfaces startups using the sequencing giant's platforms; and the partners' deep academic and industry networks across the US and Europe. This combination gives the firm early visibility into breakthroughs in single-cell analysis, spatial biology, and AI-driven drug discovery.

The firm invests primarily in North America and Europe. Its portfolio includes US-based companies like Delfi Diagnostics and Arbor Biotechnologies, as well as European companies such as Stilla Technologies (France) and Sonothera (Ireland). The firm has offices in the San Francisco Bay Area and a dedicated Europe office to serve both markets.